Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Once-a-Year Drug Helps Counter Steroid-Linked Bone Loss

Reclast injection beat daily pill at restoring bone for patients with asthma, rheumatoid arthritis, study found

By Alan Mozes
HealthDay Reporter


Related Encyclopedia
 border=
Alzheimer's Disease
Amenorrhea
Amniocentesis
Amniocentesis and CVS
More...

Related Healthscout Videos
 border=
Shingles Vaccine Debate
Pacemaker for High Blood Pressure
Managing Pain at Home
Video Game for ACL Tears
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Breast Reduction
Breast Self-Exam Video
Erectile Dysfunction
More...

Related Drug Information
 border=
Actonel
Coumadin
Detrol LA
Diflucan
More...

Related News Articles
 border=
MRI Beats X-Ray for Spotting Fractures in ER
New Down Syndrome Theory Emerges
Big Smiles, Longer Lives?
U.K. Veterinarians at Quadrupled Risk for Suicide
More...

FRIDAY, April 10 (HealthDay News) -- Patients with rheumatoid arthritis or asthma often need to take a bone-strengthening drug to counter the debilitating effects of their steroid medications.

Now, a new study finds that a once-yearly injection of a bisphosphonate bone-building drug, Reclast, may work better than a once-daily bisphosphonate pill for these patients.

Text Continues Below



Specifically, Reclast (zoledronic acid) was found to hold off and/or reverse bone loss among patients taking a glucocorticoid medication (including prednisolone or prednisone) for one of several inflammatory and immune-related diseases, including asthma, lupus and rheumatoid arthritis. And it did so more effectively than a daily dose of an oral bisphosphonate, Actonel (risedronate). Actonel is also available as a once-weekly and once-monthly pill.

The research team also found that both drugs appeared successful in lowering the risk of bone fracture that can result from glucocorticoid use.

The new study was funded by Novartis, which makes Reclast to help fight osteoporosis-linked bone loss in postmenopausal women. Novartis also makes another form of zoledronic acid, Zometa, for use by cancer patients.

"The important point is that people who take glucocorticoid steroids for asthma or arthritis are all in danger of getting osteoporosis or fractures as a consequence," said study lead author Dr. David M. Reid, professor of rheumatology and head of the division of applied medicine at University of Aberdeen, Scotland. "But now, we have found that there is a simple way of preventing that almost absolutely by applying a single infusion once a year of this safe and effective drug."

Reid and his colleagues reported their findings in the April 11 issue of The Lancet.

While bisphosphonate drugs can strengthen bone, they are not without their problems. For example, recent studies have suggested links between long-term use of oral bisphosphonates such as Fosamax (alendronate) to a heightened risk for irregular heartbeat and a particular type of fracture.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 4/13/2009

Related Links
 border=
From Healthscout's partner site on osteoarthritis, MyOsteoarthritisCentral.com
Understanding osteoarthritis symptoms and arthiritis pain
Learn about osteoarthritis treatments
How to avoid osteoarthritis with exercise





SOURCES: David M. Reid, M.D., professor, rheumatology, and head, division of applied medicine, University of Aberdeen, Aberdeen, Scotland, U.K.; Mone Zaidi, M.D., Ph.D., professor, medicine and physiology, and director, Mount Sinai Bone Program, Mount Sinai School of Medicine, New York City; April 11, 2009, The Lancet


About The HealthScout Network Contact Us
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy